Literature DB >> 26797858

PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

D Ates Ozdemir1, A Usubutun2.   

Abstract

Ovarian cancer is the most common cause of gynecologic cancer death. Both morphologically and immunohistochemically, metastatic mucinous tumors are the best mimickers of mucinous ovarian tumors; its pathogenesis still remains a mystery. PAX2 and PAX8 immunohisyochemistries are useful for differentiating numerous primary tumour types from metastatic ones. There are few studies in literature about PAX expressions in mucinous and seromucinous tumors. None of these are takes into account the histologic type (whether it is seromucinous or mucinous) or the metastatic origin. With this purpose hematoxylin and eosine slides of ovarian mucinous and seromucinous tumors were re-evaluated and one block was chosen for each case. The study included 76 ovarian mucinous and seromucinous tumors of the ovary reported in Hacettepe University department of pathology between 2000 and 2013. Tissue microarray (TMA) was designed from the chosen blocks, PAX2, PAX8, CDX2 immunostains was preformed to the TMA slides. As a result, most of the metastatic cases were negative for PAX2 (91.2 %) and PAX8 (86.3 %), many were diffusely and strongly positive for CDX2 (68.2 %). Seromucinous tumors were devoid of CDX2 expression; but all cases (except one) displayed strong and diffuse positivity with PAX8. In other words differing from mucinous tumors, seromucinous tumors show strong PAX8 positivity-similar to serous tumors. This study shows that PAX8 and CDX2 could be useful in differentiating primary mucinous from metastatic tumor. Furthermore unlike the homogeneity in seromucinous tumors for PAX8 and CDX2 mucinous tumors shows heterogeneity with different expression patterns.

Entities:  

Keywords:  Borderline seromucinous tumor; Mucinous ovarian carcinoma; Mucinous ovarian tumor; PAX2; PAX8

Mesh:

Substances:

Year:  2016        PMID: 26797858     DOI: 10.1007/s12253-016-0040-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  Ephraim McDowell, Jane Todd Crawford, and the origins of oophorectomy.

Authors:  C P McMahon
Journal:  N C Med J       Date:  2000 Jan-Feb

2.  Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases.

Authors:  Ali Dastranj Tabrizi; Steve E Kalloger; Martin Köbel; Jane Cipollone; Calvin D Roskelley; Erika Mehl; C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2010-03       Impact factor: 2.762

3.  Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases.

Authors:  Peiguo G Chu; Lawrence Chung; Lawrence M Weiss; Sean K Lau
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

4.  Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.

Authors:  J H Lagendijk; H Mullink; P J Van Diest; G A Meijer; C J Meijer
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

5.  PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.

Authors:  Ayhan Ozcan; Steven S Shen; Candice Hamilton; Kundu Anjana; Donna Coffey; Bhuvaneswari Krishnan; Luan D Truong
Journal:  Mod Pathol       Date:  2011-02-11       Impact factor: 7.842

6.  A comprehensive analysis of PAX8 expression in human epithelial tumors.

Authors:  Anna R Laury; Ruth Perets; Huiying Piao; Jeffrey F Krane; Justine A Barletta; Christopher French; Lucian R Chirieac; Rosina Lis; Massimo Loda; Jason L Hornick; Ronny Drapkin; Michelle S Hirsch
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

7.  K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.

Authors:  M Cuatrecasas; A Villanueva; X Matias-Guiu; J Prat
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

8.  Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior.

Authors:  Brigitte M Ronnett; André Kajdacsy-Balla; C Blake Gilks; Maria J Merino; Elvio Silva; Bruce A Werness; Robert H Young
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

9.  Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary.

Authors:  G Ueda; M Sawada; H Ogawa; O Tanizawa; M Tsujimoto
Journal:  Gynecol Oncol       Date:  1993-11       Impact factor: 5.482

10.  Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors.

Authors:  Jeffrey D Seidman; Fatemeh Khedmati
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

View more
  4 in total

1.  TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

Authors:  Ahmed El-Balat; Iryna Schmeil; Thomas Karn; Sven Becker; Nicole Sänger; Uwe Holtrich; Ruza Arsenic
Journal:  Pathol Oncol Res       Date:  2017-05-03       Impact factor: 3.201

2.  A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Authors:  Nicola S Meagher; Linyuan Wang; Peter F Rambau; Maria P Intermaggio; David G Huntsman; Lynne R Wilkens; Mona A El-Bahrawy; Roberta B Ness; Kunle Odunsi; Helen Steed; Esther Herpel; Michael S Anglesio; Bonnie Zhang; Neil Lambie; Anthony J Swerdlow; Jan Lubiński; Robert A Vierkant; Ellen L Goode; Usha Menon; Aleksandra Toloczko-Grabarek; Oleg Oszurek; Sanela Bilic; Aline Talhouk; Montserrat García-Closas; Qin Wang; Adeline Tan; Rhonda Farrell; Catherine J Kennedy; Mercedes Jimenez-Linan; Karin Sundfeldt; John L Etter; Janusz Menkiszak; Marc T Goodman; Paul Klonowski; Yee Leung; Stacey J Winham; Kirsten B Moysich; Sabine Behrens; Tomasz Kluz; Robert P Edwards; Jacek Gronwald; Francesmary Modugno; Brenda Y Hernandez; Christine Chow; Linda E Kelemen; Gary L Keeney; Michael E Carney; Yanina Natanzon; Gregory Robertson; Raghwa Sharma; Simon A Gayther; Jennifer Alsop; Hugh Luk; Chloe Karpinskyj; Ian Campbell; Peter Sinn; Aleksandra Gentry-Maharaj; Penny Coulson; Jenny Chang-Claude; Mitul Shah; Martin Widschwendter; Katrina Tang; Minouk J Schoemaker; Jennifer M Koziak; Linda S Cook; James D Brenton; Frances Daley; Björg Kristjansdottir; Constantina Mateoiu; Melissa C Larson; Paul R Harnett; Audrey Jung; Anna deFazio; Kylie L Gorringe; Paul D P Pharoah; Parham Minoo; Colin Stewart; Oliver F Bathe; Xianyong Gui; Paul Cohen; Susan J Ramus; Martin Köbel
Journal:  Mod Pathol       Date:  2019-06-25       Impact factor: 8.209

3.  Impact of Ovarian Metastatectomy on Survival Outcome of Colorectal Cancer Patients with Ovarian Metastasis: A Retrospective Study.

Authors:  Xiaofen Li; Hai Huang; Longyao Ran; Chao Fang; Yongyang Yu; Manxi Luo; Meng Qiu
Journal:  Cancer Manag Res       Date:  2020-06-12       Impact factor: 3.989

Review 4.  Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

Authors:  Pavel Dundr; Naveena Singh; Barbora Nožičková; Kristýna Němejcová; Michaela Bártů; Ivana Stružinská
Journal:  Diagn Pathol       Date:  2021-03-11       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.